A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Description

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Conditions

Pancreatic Cancer, Pancreatic Diseases, Pancreatitis, Pancreatic Cyst

Study Overview

Study Details

Study overview

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Middletown

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States, 07645

Cold Spring Harbor

Cold Springs Harbor Laboratory (Specimen Analysis), Cold Spring Harbor, New York, United States, 11724

Commack

Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities), Commack, New York, United States, 11725

Harrison

Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States, 10604

New York

New York University, New York, New York, United States, 10010

New York

Memorial Sloan - Kettering Cancer Center, New York, New York, United States, 10021

New York

Memorial Sloan Kettering Basking Ridge (All protocol activities), New York, New York, United States, 10065

New York

Weill Cornell Medical Center, New York, New York, United States, 10065

Rockville Centre

Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
  • * Patient planning to receive systemic treatment
  • * Hemoglobin \> 8
  • * ECOG performance status 0-2
  • * A minimum age of 18 years old
  • * Willing to undergo a tumor biopsy
  • * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
  • * Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution
  • * Patient planned to undergo upfront resection
  • * No pre-operative systemic therapy nor chemoradiation therapy planned
  • * Hemoglobin \> 8
  • * ECOG performance status 0-2
  • * A minimum age of 18 years old
  • * Willing to undergo a tumor biopsy
  • * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
  • * Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution
  • * Hemoglobin \> 8
  • * ECOG performance status 0-2
  • * A minimum age of 18 years old
  • * Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution
  • * Hemoglobin \> 8
  • * ECOG performance status 0-2
  • * A minimum age of 18 years old
  • * Confirmed diagnosis of IPMN without high risk features by the enrolling institution
  • * A minimum age of 18 years old
  • * Confirmed diagnosis of benign pancreatic cyst by the enrolling institution
  • * A minimum age of 18 years old
  • * A minimum age of 18 years old
  • * Prior chemotherapy or radiation therapy for pancreatic cancer in the advanced setting
  • * Prior chemotherapy or radiation therapy for pancreatic cancer within the last 6 months in the localized setting
  • * Prior history of another malignancy, except non-melanoma skin cancer or low grade malignancy
  • * Active second malignancy, unless low grade malignancy
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * Neoadjuvant chemotherapy or radiation therapy is planned
  • * Prior history of another malignancy, except non-melanoma skin cancer or low grade malignancy
  • * Active second malignancy, unless low grade malignancy
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * Active or prior malignancy, except prior non-melanoma skin cancer
  • * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * Active or prior malignancy, except prior non-melanoma skin cancer
  • * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * IPMN with high risk features or planned resection
  • * Active or prior malignancy, except prior non-melanoma skin cancer
  • * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * Active or prior malignancy, except prior non-melanoma skin cancer
  • * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  • * Active or prior malignancy, except prior non-melanoma skin cancer
  • * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  • * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Study Record Dates

2025-10-30